Quick answer: MOTS-c side effects in people are largely unknown, because MOTS-c has never been tested in a published human trial. FDA’s 2026 review found no human exposure data, no animal toxicity studies and no adverse event reports for it.[1] The only related human trial used a modified version called CB4211, where the only adverse events in more than 10% of people were temporary injection-site reactions.[2]
This guide explains what is and is not known: the analog trial, what users report, FDA’s safety concerns, who should be cautious and what to ask a clinician. For background, see our MOTS-c profile and the MOTS-c topic hub.
Why so little is known about MOTS-c side effects
MOTS-c is a 16-amino-acid peptide made by mitochondria. It was discovered in 2015, and nearly all research on it has been done in mice.[7] Side effects are normally learned in stages: animal toxicity studies, a first small human trial, then larger trials. MOTS-c has not completed any of these stages.
FDA’s evaluation for its July 2026 advisory meeting listed what is missing:[1]
- No human studies. FDA found no clinical studies or human exposure data for MOTS-c by any route, and said the potential safety risks in humans are unknown.
- No toxicity studies. No acute, repeat-dose, genetic, developmental or cancer-risk studies in animals were submitted or found.
- No dose-response data. Animal studies did not test how effects change with dose.
- Unknown target. The molecules MOTS-c acts on are unknown, which FDA said makes it hard to predict which organs might be affected.
FDA also searched its adverse event database (FAERS) through March 2025 and found no reports for MOTS-c. That does not mean no one has had a problem: FDA notes that most compounders do not report adverse events, so the agency may not hear about them.[1]
What the CB4211 trial found
The closest human data come from CB4211, a modified version (analog) of MOTS-c developed by CohBar. It is a different molecule, so its safety record cannot simply be transferred to MOTS-c.
The registered study was randomized, double-blind and placebo-controlled, enrolled 88 people across three parts, and was completed in April 2021.[3]
| Part | Who | Treatment |
|---|---|---|
| Phase 1a, single doses | Healthy adults | Rising single doses or placebo |
| Phase 1a, repeated doses | Healthy adults | Daily injections or placebo for 7 days |
| Phase 1b | Adults with obesity and fatty liver | 25 mg or placebo daily for 4 weeks |
Results were reported by the company in a press release, not in a peer-reviewed paper:[2]
- No serious adverse events in either part of the study.
- Injection-site reactions were the only adverse events seen in more than 10% of people on CB4211 in the 4-week phase. They were temporary and generally mild to moderate.
- Liver enzymes fell more than on placebo, but liver fat fell substantially in both groups.
In 2023, CohBar said it did not believe the CB4211 formulation used in the trial was suitable for further development.[4] No longer-term safety data were published.
Side effects reported by people using MOTS-c
The U.S. Anti-Doping Agency says that among people who claim to buy MOTS-c online, many side effects have been reported:[5]
- Faster heart rate or heart palpitations
- Irritation where it is injected
- Insomnia (trouble sleeping)
- Local or whole-body immune reactions
- Fever
USADA adds that there is no data on what happens with long-term use.[5] These are user reports, not trial findings. Without a comparison group, it is impossible to say how often they happen, or whether they come from MOTS-c, from contamination or from something else entirely.
FDA’s main concern: immune reactions
FDA’s biggest worry is immunogenicity, the chance that the body mounts an immune response against an injected peptide.[1]
- Injection under the skin raises the risk. FDA says this route is generally linked to more immune responses than giving a drug into a vein.
- Possible outcomes vary widely. They range from antibodies that cause no symptoms to life-threatening reactions, and they are often unpredictable. Antibodies can also block the peptide’s effect, or the body’s own version of it.
- Clumping and impurities add risk. Peptides can stick together (aggregate), and impurities left from manufacturing can make immune reactions more likely. FDA found no data on aggregates or impurities for MOTS-c and could not rule out these risks.
FDA also said MOTS-c is not well characterized: the free base and acetate forms are distinct substances, and available quality data did not cover impurities, aggregates or bacterial toxins (endotoxins).[1]
Theoretical effects from how MOTS-c works
In mice, MOTS-c lowered weight gain and improved insulin sensitivity on a high-fat diet, and a short obesity experiment cut blood glucose by about half.[1][7] It also changed muscle metabolism and improved exercise capacity.[8]
Those effects suggest possible changes in blood sugar, appetite or energy use in people, but this is speculation. No human study has measured them. FDA also flagged a basic unknown: human blood broke MOTS-c into shorter pieces quickly in a lab study, so it is not clear whether injected MOTS-c reaches active levels at all.[1]
Product quality and source risks
MOTS-c is not FDA-approved and is not part of any approved drug.[1] USADA warns that it is sold on websites labeled “for research purposes only” and in compounded medications.[5] Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed.[10]
In July 2026, FDA’s Pharmacy Compounding Advisory Committee voted 7 to 5, with 2 abstentions, to recommend allowing MOTS-c in compounding, against FDA scientists’ advice. The vote is not binding, and MOTS-c had not been added to the list as of our last review.[9] For what labels like these mean, see our guides to research-use-only peptides and compounded vs research-grade peptides.
Who should be especially cautious
There is no official list of people who should avoid MOTS-c, because there is no label. Based on the unknowns above, be especially careful, and talk to a clinician first, if you:
- Have diabetes or take glucose-lowering medicine, given MOTS-c’s effects on blood sugar in mice.
- Have a heart rhythm problem, given reports of palpitations.[5]
- Have an autoimmune condition or a history of drug allergies, given FDA’s immune concerns.[1]
- Are pregnant, breastfeeding or trying to conceive, since no reproductive safety studies exist.[1]
- Compete in tested sport. USADA lists MOTS-c as prohibited.[5] See peptides on the WADA prohibited list.
Questions to ask a clinician
- What human evidence supports using MOTS-c for my goal?
- Which side effects should make me stop and call you?
- How is the product’s identity, purity and sterility checked?
- Will you check blood sugar or heart rate while I use it?
- Is there an FDA-approved treatment for my condition instead?
For why no human dose exists, see our MOTS-c dosage guide. For the wider family of mitochondrial signals, see mitochondrial peptides research, and for a general overview of peptide side effects. Report any suspected reaction to your clinician and to FDA’s MedWatch program.
